Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements

Diffuse large B-cell lymphoma(DLBCL) is the most common type of non-Hodgkin lymphoma, representing approximately 30-40% of all cases.[1][1] The update of the 4th edition of the 2017 WHO classification provides new concepts in the classification of DLBCL.[1][1] Importantly, the category “B-cell